ProKidney announced results of a Phase 2 clinical trial.
The stock, which was less than $1 per share, skyrocketed on the announcement.
ProKidney (NASDAQ: PROK) shares closed at $3.73, rising 515% today while the S&P 500 fell 0.1% and the Dow Jones Industrial Average dropped 0.4%.
The chronic kidney disease-focused biotech experienced significant volatility, trading between $0.46 and $4.86 before settling near its upper range. The gain follows ProKidney’s announcement of statistically and clinically meaningful topline results from its Phase 2 REGEN-007 clinical trial evaluating is autologous cell therapy treatment, called rilparencel, in patients with chronic kidney disease and diabetes.
Competitors showed similar momentum, with FibroGen gaining 4.7% and Vertex Pharmaceuticals rising 1.5% to $466.36. FibroGen’s similar trajectory suggests sector-wide enthusiasm for kidney innovations, while Vertex’s steadier movement reflects its market maturity.
ProKidney’s proprietary React technology platform continues attracting attention as its RMCL-002 trial progresses. Unlike competitors pursuing pharmaceutical interventions, ProKidney’s focus on cellular regeneration represents a potentially transformative approach to chronic kidney disease treatment.
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,053%* — a market-crushing outperformance compared to 179% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
*Stock Advisor returns as of July 7, 2025
JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
